Seagen Inc. (SGEN)
After hours:
| Previous close | 174.00 |
| Open | 179.74 |
| Bid | 176.50 x 1200 |
| Ask | 179.13 x 1200 |
| Day's range | 173.61 - 179.95 |
| 52-week range | 105.43 - 192.79 |
| Volume | |
| Avg. volume | 1,354,301 |
| Market cap | 33.01B |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.78 |
| Earnings date | 27 July 2022 - 01 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 164.94 |
- Zacks
Seattle Genetics (SGEN) Moves 12.7% Higher: Will This Strength Last?
Seattle Genetics (SGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- Simply Wall St.
Are Investors Undervaluing Seagen Inc. (NASDAQ:SGEN) By 45%?
Does the June share price for Seagen Inc. ( NASDAQ:SGEN ) reflect what it's really worth? Today, we will estimate the...
- Business Wire
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
BOTHELL, Wash. & COPENHAGEN, Denmark, June 06, 2022--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced interim data from the innovaTV 205 trial, which included data evaluating tisotumab vedotin (TIVDAK®) in combination with pembrolizumab (Cohort E) in patients with recurrent or metastatic cervical cancer (r/mCC) who have not received prior systemic therapy, with a confirmed objective response rate (ORR) of 41% (95% Confidence Interval [CI]: 24% to 59%) and median durabilit
